3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.
Iveson T, Boyd KA, Kerr RS, Robles-Zurita J, Saunders MP, Briggs AH, Cassidy J, Hollander NH, Tabernero J, Haydon A, Glimelius B, Harkin A, Allan K, McQueen J, Pearson S, Waterston A, Medley L, Wilson C, Ellis R, Essapen S, Dhadda AS, Harrison M, Falk S, Raouf S, Rees C, Olesen RK, Propper D, Bridgewater J, Azzabi A, Farrugia D, Webb A, Cunningham D, Hickish T, Weaver A, Gollins S, Wasan H, Paul J.
Iveson T, et al. Among authors: allan k.
Health Technol Assess. 2019 Dec;23(64):1-88. doi: 10.3310/hta23640.
Health Technol Assess. 2019.
PMID: 31852579
Free PMC article.
Clinical Trial.
The health economic analysis will be updated to include long-term extrapolation for subgroups. We expect these analyses to be available in 2019-20. ...Patients were less likely to get side effects with 3-month chemotherapy. In particular, the chance of persistent long-t …
The health economic analysis will be updated to include long-term extrapolation for subgroups. We expect these analyses to be availab …